Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomePROCEPT BioRobotics CorporationNIH and Clinical Excellence in the UK issued an Interventional Procedure Guidance Recommendation Approving Use of Aquablation® Therapy as an Alternative to Other Surgical Techniques for RX of BPH

NIH and Clinical Excellence in the UK issued an Interventional Procedure Guidance Recommendation Approving Use of Aquablation® Therapy as an Alternative to Other Surgical Techniques for RX of BPH

Enhanced Guidance and Incremental Reimbursement Will Strengthen Continued Global Growth of Aquablation® Therapy for the Treatment for Benign Prostatic Hyperplasia (BPH)

The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK) has issued an Interventional Procedure Guidance (IPG) recommendation approving the use of Aquablation® therapy as an alternative to other surgical techniques for the treatment of BPH, a non-cancerous enlargement of the prostate. The recommendation opens the door for wider spread use in the UK’s National Health Service (NHS).

Additionally, the company announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP), which provides incremental payment for devices used in the inpatient setting for Aquablation therapy with the AQUABEAM® Robotic System. The NTAP program is only available to new technologies meeting a number of criteria including demonstrating substantial clinical improvement over existing surgical techniques.

“The NICE guidance is the first step in gaining full endorsement for widespread use of Aquablation in the UK,” said Nikolai Aljuri, PhD, PROCEPT BioRobotics co-founder, CEO and president. “In addition, the recent CMS NTAP designation recognizes Aquablation therapy as a substantial clinical improvement compared to other surgical techniques for BPH and aligns with our vision of making Aquablation therapy the new standard of care and treatment of choice for BPH.”

“Studies comparing Aquablation therapy to TURP demonstrate that this new approach delivers outcomes like TURP but with a far lower risk of sexual dysfunction,” said Neil Barber, consultant urological surgeon at Frimley Park Hospital in Surrey. “The AQUABEAM Robotic System offers a solution for patients regardless of prostate size and shape. The procedure is predictable and has provided reproducible outcomes, as it allows me to plan the surgery via ultrasound and then perform a controlled resection of the prostate via the autonomous AQUABEAM robot.”

The full guidance document can be accessed here: NICE will review this guidance on Aquablation again in 2021.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy